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Abstract
Background: The proteolysis-inducing factor (PIF) was identified as a tumour product in various
gastrointestinal cancers. A previous study in pancreatic cancer patients suggested PIF expression as
a tumour marker, which is not related to tumour size. We hypothesized that PIF could be a useful
marker to exclude benign pancreatic tumors, as chronic pancreatitis with a pancreatic mass.
Methods: Urine of patients with a pancreatic mass of uncertain malignancy was investigated for
PIF expression by Western blot. Sufficient urine protein for analysis was available in 59 patients.
The diagnosis was established by histology in 54 patients and by follow up in five patients with
chronic pancreatitis. In addition, serum CA19-9 was measured.
Results: The sensitivity (specifity) for the detection of a malignant pancreatic tumour was 90%
(75%) and 54% (71%) for CA19-9 and PIF, respectively. The sensitivity (specifity) for the distinction
of pancreatic cancer from chronic pancreatitis was 89% (80%) and 57% (63%) for CA19-9 and PIF,
respectively.
Conclusion: Evaluation of PIF in urine is of no diagnostic value in patients with a pancreatic mass
of unknown malignancy.
Background
Distinction between benign and malignant pancreatic
tumours is still difficult, despite significant progress in
imaging techniques. Patients with chronic pancreatitis are
at increased risk to develop pancreatic cancer [1]. Pancre-
atic inflammation, as observed in chronic pancreatitis,
can be mistaken on imaging as cancer and inversely.
Serum carbohydrate antigen 19-9 (CA19-9) levels are ele-
vated in 80% of pancreatic cancer patients, but can also be
increased in 20% of patients with chronic pancreatitis [2].
An accurate and non-invasive test to differentiate pancre-
atic cancer from chronic pancreatitis is not available.
Cancer frequently induces cachexia, but not all cancer
patients will develop cachexia. This is not necessarily a
late phenomenon in tumour progression. It may be
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present at diagnosis and may be the leading symptom that
induces search for a tumour. A study of pancreatic cancer
patients revealed that patients had lost a median of about
14% of their usual body weight at the time of diagnosis,
and that this weight loss was progressive, increasing to a
median of 25% at the time of the last assessment [3]. The
central role in this process of – predominant – skeletal
muscle waste seems to play the proteolysis-inducing fac-
tor (PIF) [4].
PIF is a 24-kDa sulphated glycoprotein synthesized by
cachexia-inducing murine and human tumours, which
induces catabolism of myofibrillar proteins in skeletal
muscle via a direct stimulation of the proteasome path-
way in muscle cells [5]. Administration of PIF to normal
mice leads to a rapid decrease in body weight, which is
based primarily on a loss of skeletal muscle mass [4,6].
PIF is expressed in a variety of gastrointestinal cancers [7].
It was detected in the urine of 44 from 55 pancreatic can-
cer patients, who had a significantly greater total weight
loss and rate of weight loss than patients whose urine did
not contain PIF. Interestingly, PIF expression was not
dependent on cancer stage, but seemed to be a qualitative
marker of pancreatic cancer: even stage 2 tumours
expressed PIF in 83 per cent [8].
PIF has not been investigated in benign pancreatic dis-
eases. We therefore hypothesized that PIF production in
patients with a pancreatic tumour would clearly indicate
the malignant nature of the disease. Special attention was
paid to a clear distinction to a pancreatic mass caused by
chronic pancreatitis.
Methods
100 patients with a pancreatic mass of uncertain malig-
nancy (detected by computed tomography, magnet reso-
nance tomography, ultrasound and/or endoscopic
retrograde cholangiopancreaticography) were investi-
gated. Patients with UICC stage 4 (locally extended and
metastasised disease) were not enrolled. After collection
of urine from all study participants, we investigated 30 ml
urine for the presence of PIF with a specific mouse mono-
clonal antibody in a Western blot setting as described
recently [4,8]. In brief, urine protein was precipitated with
ammonium sulphate and dialysed against water between
12 and 15 hours (overnight) with a molecular weight cut-
off of 10 kD (Slide-A-Lyzer Dialysis Cassette). 5 µg of con-
centrated samples were separated with sodium dodecyl-
sulphate polyacrylamide gel electrophoresis and
subsequently blotted on nitrocellulose membranes. After
incubation with 10 µg/ml of the mouse monoclonal PIF
antibody (provided with courtesy by MJ Tisdale) and
streptavidine horseradish peroxidase conjugate, the bands
were detected using the Fluorescent ECL Plus system
(Amersham). In addition, CA19-9 in serum was measured
with an electrochemiluminescence immunoassay (CA19-
9®Roche Diagnostics or ADVIA Centaur®, Bayer Health-
care), the upper limit of normal was 22 U/ml. The ethics
committees of the three participating centres approved
this protocol.
Results and discussion
The analysis failed in 41 patients due to insufficient
amount of urinary protein after dialysis. In 59 patients,
PIF Western blot was successfully performed (figure 1).
This cohort was subsequently assessed: it included 31
male and 28 female patients (median age 59 years, range
33–89 years). The diagnoses of the patients were shown in
figure 2. Final diagnosis was done by histology in 54
patients or follow up for at least one year in five patients
with chronic pancreatitis, who did not undergo surgery.
The diagnostic values of PIF for the detection of a malig-
nant pancreatic tumour and with special attention to pan-
creatic cancer are shown in table 1. Summarizing all 59
patients, the median CA19-9 values in patients with
benign or malignant pancreatic tumours were 16.5
(standard deviation (SD): 141) and 477 (SD: 22173 U/l),
respectively (p < 0.05). The median CA19-9 values in
patients with chronic pancreatitis and pancreatic cancer
were 15.0 (SD: 18) and 478.5 U/l (SD: 22022), respec-
tively (p < 0.05). The analysis of CA19-9 in dependence
on the presence of PIF in urine in PIF negative patients
revealed 22.5 U/l (SD: 742) and 580.5 U/l in PIF positive
patients (SD: 25203) (p < 0.05). PIF was detected in two
patients with CA19-9 negative pancreatic cancer, but was
not detectable in 16 pancreatic cancer patients (15 of
them with elevated CA19-9).
This is the first attempt to evaluate the proteolysis-induc-
ing factor as a diagnostic marker of pancreatic cancer in
patients with a potentially resectable pancreatic tumour.
We found a weak association with malignancy, but the
diagnostic value to distinguish benign from malignant
pancreatic tumours is lower than CA19-9. PIF seems to be
of a rather limited importance to answer this question in
every-day care.
A major drawback of our data is the high amount of
patients with insufficient urinary protein after extraction
and dialysis. For practical reasons in this multi-centre col-
laboration, we tried to investigate PIF in a small urine
sample, as initially suggested by Todorov et al. [4]. Our
problem could be potentially solved by the collection of
higher urine volumes in further studies.
PIF was detected in 6 patients with chronic pancreatitis
without evidence for a malignancy by 12 months follow
up or histology. This raises the question about the originBMC Gastroenterology 2005, 5:20 http://www.biomedcentral.com/1471-230X/5/20
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of PIF in these patients. Although the majority of investi-
gations found PIF expression only in tumour tissue, the
expression of PIF in non-malignant tissue has been also
reported [7]. The primary role of PIF seems to be in regu-
lation of development [9]. After cloning of the cDNA for
PIF, a human homologue – the human cachexia associ-
ated protein (HCAP) – has been identified, which is min-
imally expressed in normal tissues [10,11]. It can be
speculated, that the ongoing inflammation in patients
with chronic pancreatitis is capable to generate PIF. This
could explain the low specifity of PIF to detect pancreatic
malignancies in our study. Three patients with pancreatic
cancer had normal CA19-9 values, two of them were PIF-
positive. A sequential testing of PIF in the case of a CA19-
9-negative pancreatic tumour may be beneficial but has to
be considered cautiously based on these small patient
numbers. However, even this approach would fail to
detect all pancreatic cancer patients in our study.
Although our data indicate that PIF is not helpful as a
diagnostic marker of pancreatic cancer, a benefit may be
the early identification of patients who need nutritional
intervention [12]. In previous studies the detection of PIF
was associated with prior weight loss. PIF induces an
increase of the ubiquitin – proteasome activity resulting in
protein catabolism. Administration of the polyunsatu-
rated fatty acid eicosapentaenoic acid (EPA) attenuates
protein degradation by antagonizing the PIF induced up
regulation of the ubiquitin – proteasome proteolytic path-
way in cachectic tumour bearing mice [13]. A first
Western blot analysis for PIF after urinary protein extraction Figure 1
Western blot analysis for PIF after urinary protein extraction. Lane 1: Rainbow® recombinant protein molecular weight marker 
(#RPN 800, Amersham Life Science); lane 2: healthy control person, lanes 3 and 5: chronic pancreatitis, PIF not detected, lanes 
4 and 7: pancreatic cancer, UICC stage 1 and 2, respectively, PIF detected (24 kD, broken line); lanes 6: chronic pancreatitis, 
PIF detected; lane 8: positive control (pancreatic cancer, UICC stage 4)
1          2         3         4         5          6          7 8
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randomised placebo – controlled trial in patients with
pancreatic cancer suggest that a EPA enriched oral
supplement has the potential to induce a net gain of
weight, lean body mass and improvement of quality of
life [14].
Conclusion
PIF is not superior to the established tumour marker
CA19-9 to distinguish benign from malignant pancreatic
tumours. Further investigations should clarify whether the
onset of PIF expression in the long-term follow-up of
chronic pancreatitis patients is associated with early
malignancy and whether it precedes morphologic and
clinical signs of pancreatic cancer. In future, the evalua-
tion of PIF as an indicator for early nutritional interven-
tion seems to be warranted.
Abbreviations
proteolysis-inducing factor PIF
Diagnoses in PIF positive and PIF negative patients Figure 2
Diagnoses in PIF positive and PIF negative patients
Table 1: Diagnostic values of PIF in comparison to CA19-9 to discriminate malignant vs. benign and pancreatic cancer (PaCa) vs. 
chronic pancreatitis (CP).
all malignant vs. all benign PaCa vs. CP
PIF CA19-9 PIF CA19-9
Sensitivity 5 4 %9 0 %5 7 %8 9 %
Specifity 7 1 %7 5 %6 3 %8 0 %
positive predictive 
value
7 3 %8 8 %7 4 %9 3 %
negative predictive 
value
5 2 %8 0 %4 4 %7 3 %
59 patients
26 PIF positive










-3 intraductal papillary mucinous tumor
-2 choledochitis





-1 pancreatic metastasisPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2005, 5:20 http://www.biomedcentral.com/1471-230X/5/20
Page 5 of 5
(page number not for citation purposes)
pancreatic cancer PaCa
chronic pancreatitis CP




The author(s) declare that they have no competing
interests.
Authors' contributions
N.T and J.O. had the initial idea and initiated the study.
N.T. co-ordinated the laboratory analysis. All authors
ascertained patients in this multicenter investigation,
wrote and discussed the final manuscript.
Acknowledgements
We thank Professor M.J. Tisdale for kindly providing the anti-PIF-antibody. 
We furthermore thank S. Kistner and T. Herrmann for expert technical 
assistance.
References
1. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, Levy P,
Ruszniewski P: Risk of pancreatic adenocarcinoma in chronic
pancreatitis.  Gut 2002, 51:849-52.
2. Satake K, Takeuchi T: Comparison of CA19-9 with other tumor
markers in the diagnosis of cancer of the pancreas.  Pancreas
1994, 9:720-724.
3. Wigmore SJ, Plester CE, Richardson RA, Fearon KCH: Changes in
nutritional status associated with unresectable pancreatic
cancer.  Br J Cancer 1997, 75:106-109.
4. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M:
Characterization of a cancer cachectic factor.  Nature 1996,
379:739-42.
5. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ:
Activation of ATP-ubiquitin-dependent proteolysis in skele-
tal muscle in vivo and murine myoblasts in vitro by a prote-
olysis-inducing factor (PIF).  Br J Cancer 2001, 85:297-302.
6. Tisdale MJ: The 'cancer cachectic factor'.  Support Care Cancer
2003, 11:73-78.
7. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava
P, Wainer IW: Proteolysis-inducing factor is expressed in
tumours of patients with gastrointestinal cancers and corre-
lates with weight loss.  Br J Cancer 2001, 84:1599-1601.
8. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon
KCH:  Characteristics of patients with pancreatic cancer
expressing a novel cancer cachectic factor.  Br J Surg 2000,
87:53-58.
9. Caruik P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ:
Induction of cachexia in mice by a product isolated from the
urine of cachectic cancer patients.  Br J Cancer 1997, 76:606-613.
10. Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S,
Schirle M, Schroeder K, Blin N, Meier F, Rassner G, Garbe C: Der-
mcidin: a novel antibiotic peptide secreted by sweat glands.
Nat Immunol 2001, 2:1133-1137.
11. Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domen-
ici J, Bae YK, Monitto CL, Merlos-Suarez A, Chan J, Hulette CM, Rich-
ardson A, Morton CC, Marks J, Duyao M, Hruban R, Gabrielson E,
Gelman R, Polyak K: A neural survival factor is a candidate
oncogene in breast cancer.  Proc Natl Acad Sci USA 2003,
100:10931-10936.
12. Ockenga J, Pirlich M, Gastell S, Lochs H: Tumoranorexie –
Tumorkachexie in der Gastroenterologie: Standards und
Visionen.  Z Gastroenterol 2002, 40:929-936.
13. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ: Mechanism of
attenuation of skeletal muscle protein catabolism in cancer
cachexia by eicosapentaenoic acid.  Cancer Res 2001,
61:3604-3609.
14. Fearon KC, von Meyenfeldt MF, Moses AG, van Geenen R, Roy A,
Gouma DJ, Giacosa A, van Gossum A, Bauer J, Barber MD, Aaronson
NK, Voss AC, Tisdale MJ: Effect of a protein and energy dense
N-3 fatty acid enriched oral supplement on loss of weight
and lean tissue in cancer cachexia: a randomised double
blind trial.  Gut 2003, 52:1479-1486.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/5/20/pre
pub